$CYTK News

Is Cytokinetics (CYTK) A Bargain On Myqorzo Approval Or Already Fully Priced?

How Myqorzo’s Commercial Launch At Cytokinetics (CYTK) Has Changed Its Investment Story

RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $117

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Cytokinetics To Present Late Breaking Science At ESC Congress, Including Phase 3 ACACIA‑HCM Results

Is Cytokinetics, Incorporated (CYTK) A Good Stock To Buy Now?

Cytokinetics Seen Gaining From Myqorzo Momentum to Treat Heart Conditions, UBS Says

UBS Upgrades Cytokinetics to Buy, Raises Price Target to $115

Mizuho Maintains Outperform on Cytokinetics, Raises Price Target to $118

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?

Needham Reiterates Buy on Cytokinetics, Maintains $102 Price Target

Cytokinetics (CYTK) Launches MYQORZO in Germany for Obstructive HCM Treatment

Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

First MYQORZO Launch In Germany Might Change The Case For Investing In Cytokinetics (CYTK)

Cytokinetics Opens Applications for Corporate Giving Program, to Fund Health, Science Education and Community Nonprofits

Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Cytokinetics Announces First Commercial European Launch Of MYQORZO In Germany For Treatment Of Symptomatic Obstructive Hypertrophic Cardiomyopathy In Adult Patients